COVID-19TYK2:

Shaohua Xu1, Jiwu Kong1

  • 1Drug Clinical Trial Center, Gansu Wuwei Tumor Hospital, 16 Xuanwu Road, Wuwei, Gansu, China.

The new microbiologica
|December 23, 2025
PubMed
概括

氨酸激酶2 (TYK2) 基因表达增加了COVID-19的风险,包括严重疾病和住院治疗. 抑制TYK2可能会降低这些风险,这表明TYK2是COVID-19治疗的潜在治疗标.